Please login to the form below
Seattle Genetics
This page shows the latest Seattle Genetics news and features for those working in and with pharma, biotech and healthcare.
Merck signs separate agreements with Seattle Genetics for two cancer drugs
Seattle Genetics will also be eligible for further progress-dependent milestone payments of up to $2.6bn. ... Seattle Genetics will receive $85m in prepaid research and development payments to be applied to Merck’s global development funding obligations
Latest news
-
Seattle Genetics wins FDA priority review for oral HER2 drug
If approved will compete with AZ/Daiichi Sankyo's Enhertu. Seattle Genetics has scored a US Food and Drug Administration (FDA) priority review for its oral HER2 inhibitor tucatinib in breast ... Seattle is seeking approval for tucatinib in combination
-
Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer
Seattle Genetics and partner Astellas have reported positive results from an early clinical trial of their antibody drug conjugate Padcev in combination with Merck &Co/MSD’s Keytruda in first-line ... line setting," said Roger Dansey, chief medical
-
AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu
In the meantime, further HER2 competition could be coming from Seattle Genetics’ oral drug tucatinib, which recently cleared the phase 3 HER2CLIMB trial as an add-on to Herceptin plus
-
J&J taps TARIS Biomedical for novel bladder cancer technology
However, J&J is not alone in the bladder cancer market. Seattle Genetics and Astellas claimed approval in the US for Padcev (enfortumab vedotin) last week, as a later-line therapy
-
Seattle, Astellas bag speedy FDA okay for bladder cancer drug
Plans to expand use into earlier bladder cancer treatment. Seattle Genetics and Astellas have claimed approval in the US for Padcev, an antibody-drug conjugate (ADC), as a later-line therapy ... That would drive a sizeable step up in Seattle’s turnover,
More from news
Approximately 12 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Winding back to last February (DW Issue 80), Immunomedics announced a licensing agreement with
-
Deal Watch March 2017
In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... sacituzumab govitecan after announcing the deal with
-
Deal Watch February 2017
Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.
-
Pharma deals in June 2015
NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology for 2 antibodies (platform).
-
Deal Watch table for September 2014
244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
Prior to this, he served as executive vice president of commercial for Seattle Genetics, where he led all commercial activities for the company.
-
Douglas Williams named president and CEO of Codiak
These included serving as chief scientific officer and executive vice president of research and development at Seattle Genetics and as senior vice president and Washington site leader at Amgen.
-
VentiRx appoints James Kyle Bryan as chief medical officer
Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Account Director
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
-
Medical Editor
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Celltrion’s investigational mAb cuts COVID-19 recovery time
- PHE study finds people who have had COVID-19 can still transmit the virus
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- PHE study finds people who have had COVID-19 can still transmit the virus
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- Experimental Chinese COVID-19 vaccine is safe, according to researchers
- EU proposes vaccine-sharing mechanism with low-income countries
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- WHO’s director-general deems vaccine nationalism a “catastrophic moral failure”
- Lilly partners with Merus on development of bispecific antibodies for cancer
- Medical research charities need our help – support is needed to continue funding life-saving research and improving lives
- Research Partnership appoints Hannah Osborn to MedTech director role
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- Recent years have seen a significant shift in drug development to specialty areas...
- 2020 - a year to remember or forget?
- 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
- The search for effective drug treatments for COVID-19
- PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
Quick links
Infographics
